top of page
Grey Round Patterns
Sherringford's logo
You can find all our articles at portalnotes.app
We have moved to sherringford.org and portalnotes.app

Novo Nordisk sues Hims & Hers over "Copycat" Obesity Drugs

Feb 9
2 min read
This conceptual image features the name "novo nordisk" in blue alongside a wooden judge's gavel, suggesting legal or regulatory themes related to the pharmaceutical company against a technical gray background.

The burgeoning market for weight-loss medications faces a major legal reckoning as Novo Nordisk filed a lawsuit Monday against the telehealth provider Hims & Hers. The suit alleges that the platform has been mass-marketing "untested" and "unapproved" compounded versions of Novo's blockbuster obesity treatments, Wegovy and semaglutide.


The legal escalation follows a turbulent weekend for Hims & Hers, which saw its stock plunge more than 27% on Monday. The company had recently announced plans to offer a compounded oral version of semaglutide for as little as $49 a month—roughly $100 cheaper than Novo’s newly launched Wegovy pill. However, Hims abruptly retreated from the pill's launch following intense scrutiny from federal regulators and the Department of Health and Human Services (HHS), which referred the company to the Department of Justice (DOJ) for investigation.


Novo Nordisk is asking the court to permanently ban Hims from selling these compounded versions, arguing they infringe on patents valid through 2032. John Kuckelman, Novo’s general counsel, described the marketing of these drugs as a "complete sham," asserting that because official shortages of semaglutide have been resolved, the regulatory loophole allowing for mass compounding has closed.


Hims & Hers defended its practices in a statement, calling the lawsuit a "blatant attack" on consumer choice and "personalized care". The company maintains that its versions are legal because they offer tailored dosages for individual patients.


The FDA has also stepped in, pledging "decisive steps" to restrict active ingredients used in non-approved compounded drugs. While Novo's shares rose 3% on the news, the legal battle marks a significant turning point for the telehealth industry, which has thrived on providing affordable alternatives during recent drug shortages.



🔖 Sources






Keywords: Novo Nordisk sues Hims & Hers

Novo Nordisk sues Hims & Hers



Sherringford logo

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating

We designed Sherringford.org to be more than just an educational resource; it is a platform created to bring a fresh perspective to your daily professional life.

 

To achieve this ambitious goal, we decided to upgrade our site, and we invite you to visit our new space at

 

sherringford.org

​

We designed Sherringford.org to be more than just an educational resource; it is a platform created to bring a fresh perspective to your daily professional life.

 

To achieve this ambitious goal, we decided to upgrade our site, and we invite you to visit our new space at sherringford.org.

bottom of page